Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Non Operating Income (2020 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Non Operating Income for 6 consecutive years, with $305000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income changed N/A to $305000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $90.7 million through Dec 2025, up 8967.3% year-over-year, with the annual reading at $302000.0 for FY2025, 7650.0% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $305000.0 at Whitehawk Therapeutics, down from $2.1 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $88.2 million in Q1 2025, with the low at -$1.4 million in Q1 2021.
  • Average Other Non Operating Income over 5 years is $7.6 million, with a median of $305000.0 recorded in 2025.
  • The sharpest move saw Other Non Operating Income crashed 100.06% in 2024, then skyrocketed 8823500.0% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$45000.0 in 2021, then surged by 1348.89% to $562000.0 in 2022, then surged by 998.04% to $6.2 million in 2023, then crashed by 83.78% to $1.0 million in 2024, then crashed by 69.53% to $305000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $305000.0, $2.1 million, and $88.2 million for Q4 2025, Q2 2025, and Q1 2025 respectively.